(Q42835370)

8 November 2017

0 references

Mechanism-based engineering against anthracycline cardiotoxicity (English)

1 reference

8 November 2017

1

1 reference

8 November 2017

2

1 reference

PMC publication ID

3856339

8 November 2017

language of work or name

English

0 references

publication date

11 June 2013

1 reference

8 November 2017

1 reference

8 November 2017

128

1 reference

8 November 2017

2

1 reference

8 November 2017

98-100

1 reference

An engineered bivalent neuregulin protects against doxorubicin-induced cardiotoxicity with reduced proneoplastic potential.

8 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3856339

The HER2 amplicon in breast cancer: Topoisomerase IIA and beyond.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3856339

Identification of the molecular basis of doxorubicin-induced cardiotoxicity

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3856339

Cardiac side effects of anticancer treatments: new mechanistic insights

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3856339

Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3856339

Neuregulin1 as novel therapy for heart failure

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3856339

Engineered bivalent ligands to bias ErbB receptor-mediated signaling and phenotypes.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3856339

Cardiovascular disease: cause of morbidity and mortality in adult survivors of childhood cancers

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3856339

Cardiotoxicity of anticancer treatments: what the cardiologist needs to know

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3856339

Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. phase II Study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3856339

Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3856339

Antioxidants and cancer therapy: a systematic review

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3856339

Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3856339

Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3856339

Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3856339

Risk factors for doxorubicin-induced congestive heart failure

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3856339

‘Daunomycin’, a New Antibiotic of the Rhodomycin Group

27 May 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23757311

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23757311

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1161/CIRCULATIONAHA.113.003688

1 reference

8 November 2017

1 reference

PMC publication ID

3856339

8 November 2017

PubMed publication ID

23757311

1 reference

PMC publication ID

3856339